GLP-1 Agonists in Methadone Patients With Opioid Use Disorder and Diabetes
- How GLP-1 receptor agonists affected cardiovascular and metabolic outcomes in methadone-treated patients with both OUD and type 2 diabetes over one year
- Whether GLP-1 RAs were associated with OUD remission, overdose reduction, and improvements in psychiatric outcomes in this high-risk population
- What the data show about suicidal ideation and attempts, depression, and anxiety in the GLP-1 RA group versus matched controls
- Where the evidence is genuinely compelling and where a careful reader should pause before drawing causal conclusions
TL;DR: In a propensity score-matched cohort of 2,314 methadone-treated adults with opioid use disorder and type 2 diabetes, GLP-1 receptor agonist use was associated with significantly lower rates of myocardial infarction, opioid overdose, suicidal ideation or attempts, major depression, and anxiety, along with higher rates of OUD remission — but causality cannot be established from this observational design.
Abstract
Aims/Hypothesis: To investigate whether the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in methadone-treated patients with opioid use disorder (OUD) and type 2 diabetes (T2D) is associated with improved cardiometabolic and mental health outcomes.
Methods: This retrospective population-based cohort study of adults (≥18 years) on methadone with both OUD and T2D (hemoglobin A1c ≥6.5%) was conducted between January 1, 2015, and October 1, 2024, using the TriNetX database. The cohort was divided into two groups, adjusted for baseline characteristics through propensity score matching (PSM), based on whether individuals had received GLP-1 RA prescriptions. Cox proportional hazard regression models were used to evaluate the association between GLP-1 RAs and the risk of incident physical and mental health outcomes over a one-year follow-up period.
Results: After PSM, 1,157 patients (mean [SD] age, 57.3 [11.1] years; 577 females [49.9%]) were prescribed GLP-1 RAs. Use of GLP-1 RAs was associated with a decreased incidence of myocardial infarctions (HR, 0.58; 95% CI, 0.41–0.80) and hypoglycemia (HR, 0.50; 95% CI, 0.33–0.77). Patients treated with GLP-1 RAs were more likely to enter OUD remission (HR, 1.75; 95% CI, 1.24–2.47) and fewer had episodes of major depression (HR, 0.71; 95% CI, 0.61–0.81), anxiety disorders (HR, 0.77; 95% CI, 0.67–0.88), and suicidal thoughts or behaviors (HR, 0.27; 95% CI, 0.16–0.47).
Conclusions/Interpretation: GLP-1 RA use in adults on methadone with both OUD and T2D was associated with lower rates of cardiometabolic and mental health complications. Randomized prospective trials are warranted to ascertain causality and clinical efficacy.
Source: Pan JY, Elman I, Panchal K, et al. GLP-1 Receptor Agonist Treatment and Health Outcomes in Methadone-Treated Patients with Opioid Use Disorder and Diabetes. J Gen Intern Med. 2026. DOI: 10.1007/s11606-026-10515-2
Study at a Glance
| Design | Retrospective propensity score-matched cohort study using the TriNetX federated database |
| Population | Adults ≥18 years with OUD on methadone and T2D (HbA1c ≥6.5%), identified January 1, 2015 to October 1, 2024 |
| Total N (before PSM) | 9,011 (1,663 on GLP-1 RAs; 7,348 not on GLP-1 RAs) |
| N after PSM | 1,157 per group (2,314 total) |
| Intervention | GLP-1 RA prescription (semaglutide, dulaglutide, liraglutide, exenatide, tirzepatide, or lixisenatide) — at least 2 prescriptions ≥6 months apart |
| Comparator | Other antidiabetic medications, no GLP-1 RA exposure |
| Follow-up | One year from index event |
| Key Finding | GLP-1 RA use was associated with 42% fewer myocardial infarctions, 75% higher OUD remission rate, and 73% fewer suicidal ideations or attempts |
Study Snapshot
| Outcome | GLP-1 RA (n=1,157) | No GLP-1 RA (n=1,157) | HR (95% CI) | p-value |
|---|---|---|---|---|
| OUD Remission | 89 (7.7%) | 51 (4.4%) | 1.75 (1.24–2.47) | 0.001 |
| Opioid Overdose | 45 (3.9%) | 81 (7.0%) | 0.55 (0.38–0.79) | 0.001 |
| Myocardial Infarction | 56 (4.8%) | 95 (8.2%) | 0.58 (0.41–0.80) | 0.001 |
| Hypoglycemia | 31 (2.7%) | 61 (5.3%) | 0.50 (0.33–0.77) | 0.001 |
| Major Depression | 326 (28.2%) | 422 (36.5%) | 0.71 (0.61–0.81) | <0.001 |
| Anxiety Disorders | 392 (33.9%) | 466 (40.3%) | 0.77 (0.67–0.88) | <0.001 |
| Suicidal Ideation/Attempts | 16 (1.4%) | 58 (5.0%) | 0.27 (0.16–0.47) | <0.001 |
| ED Visits / Hospitalizations | 620 (53.6%) | 769 (66.5%) | 0.63 (0.57–0.70) | <0.001 |
| Alcohol Use Disorder | 34 (2.9%) | 56 (4.8%) | 0.60 (0.39–0.92) | 0.017 |
| Tobacco Use Disorder | 322 (27.8%) | 401 (34.7%) | 0.73 (0.63–0.85) | <0.001 |
| Homelessness | 11 (1.0%) | 24 (2.1%) | 0.46 (0.23–0.94) | 0.029 |
Study Facts Table
| Authors | Pan JY, Elman I, Panchal K, Ramsey KM, Albanese M, Elman DJ, Ramsey DJ |
| Journal | Journal of General Internal Medicine |
| Year | 2026 (accepted May 6, 2026; published online May 18, 2026) |
| DOI | 10.1007/s11606-026-10515-2 |
| Design | Retrospective population-based cohort study with 1:1 propensity score matching |
| Database | TriNetX Research Network (federated, international, multi-institutional electronic health records) |
| N (after PSM) | 2,314 (1,157 per group) |
| Intervention | GLP-1 RA prescription (semaglutide, dulaglutide, liraglutide, exenatide, tirzepatide, or lixisenatide); minimum 2 prescriptions ≥6 months apart |
| Comparator | Other antidiabetic medications with no GLP-1 RA exposure |
| Population | Adults ≥18 years, OUD on methadone, T2D with HbA1c ≥6.5%; mean age ~57 years, ~50% female |
| Primary Endpoint | Incidence of cardiometabolic, mental health, and healthcare utilization outcomes at one year |
| Key Results | MI: HR 0.58; hypoglycemia: HR 0.50; OUD remission: HR 1.75; overdose: HR 0.55; suicidal ideation/attempts: HR 0.27; depression: HR 0.71; anxiety: HR 0.77; ED/hospitalization: HR 0.63 |
| Adverse Events | Not systematically reported as adverse events; falsification outcomes (falls, impacted cerumen) showed no between-group differences |
| Funding | No financial support received for research, authorship, or publication |
| COI | D.J. Ramsey: consultant for Regeneron Pharmaceuticals and Beaver-Visitec International. All other authors: no proprietary or commercial interest declared. |
What Researchers Actually Did
Pan, Elman, and colleagues queried the TriNetX Research Network database, a large federated repository of de-identified electronic health records spanning multiple institutions internationally, to identify adults aged 18 years or older with a documented diagnosis of OUD who were actively treated with methadone and who also carried a diagnosis of T2D confirmed by an HbA1c of at least 6.5%. Patients were classified into two groups: those who had received at least two GLP-1 RA prescriptions issued no less than six months apart (the treatment group) and those who were treated with other antidiabetic agents and had no documented GLP-1 RA exposure (the control group). The study period spanned January 1, 2015 through October 1, 2024, and all outcomes were assessed during the one-year window following the index event, defined as the date of the second GLP-1 RA prescription for the treatment group and the date of meeting inclusion criteria for the control group.
Before matching, the GLP-1 RA group skewed older and included a higher proportion of females, with substantially greater rates of hypertension, dyslipidemia, ischemic heart disease, chronic kidney disease, and obstructive sleep apnea, as well as heavier concurrent use of insulin, metformin, and SGLT2 inhibitors. This pre-match imbalance is clinically important because it suggests that sicker, more closely monitored patients were more likely to receive GLP-1 RAs, a classic healthy-user confound operating in reverse. The authors applied 1:1 greedy nearest-neighbor propensity score matching with a caliper of 0.1 standard deviations, achieving standardized mean differences below 0.1 for nearly all matched variables. After matching, 1,157 patients remained in each group. Cox proportional hazard regression models were used for all time-to-event analyses, and falsification endpoint analysis using falls and impacted cerumen was performed to probe for residual systematic bias.
Key Findings: Primary Outcomes
- Myocardial infarction: 56 events in the GLP-1 RA group versus 95 in controls (HR, 0.58; 95% CI, 0.41–0.80; p=0.001), representing a 42% relative risk reduction.
- Ischemic stroke: 72 versus 94 events (HR, 0.78; 95% CI, 0.55–1.11; p=0.164) — no statistically significant difference between groups.
- Hypoglycemia: 31 versus 61 events (HR, 0.50; 95% CI, 0.33–0.77; p=0.001), a 50% relative hazard reduction.
- OUD remission: 89 versus 51 events (HR, 1.75; 95% CI, 1.24–2.47; p=0.001) — GLP-1 RA-treated patients were 75% more likely to achieve documented OUD remission.
- Opioid overdose: 45 versus 81 events (HR, 0.55; 95% CI, 0.38–0.79; p=0.001), a 45% relative hazard reduction.
- Suicidal ideation or attempts: 16 versus 58 events (HR, 0.27; 95% CI, 0.16–0.47; p<0.001) — this is the most striking finding in the psychiatric domain, a 73% relative hazard reduction.
- Major depressive episodes: 326 versus 422 events (HR, 0.71; 95% CI, 0.61–0.81; p<0.001).
- Anxiety disorders: 392 versus 466 events (HR, 0.77; 95% CI, 0.67–0.88; p<0.001).
Key Findings: Secondary Outcomes and Subgroup Analyses
- Alcohol use disorder: 34 versus 56 events (HR, 0.60; 95% CI, 0.39–0.92; p=0.017). The authors note that the known synergistic interaction between methadone and ethanol may have partially attenuated any GLP-1 RA signal in this domain.
- Tobacco use disorder: 322 versus 401 events (HR, 0.73; 95% CI, 0.63–0.85; p<0.001).
- Homelessness: 11 versus 24 events (HR, 0.46; 95% CI, 0.23–0.94; p=0.029) — this is a social determinant outcome rarely captured in pharmacotherapy trials.
- ED visits or hospitalizations: 620 versus 769 events (HR, 0.63; 95% CI, 0.57–0.70; p<0.001).
- Ambulatory visits: 1,101 versus 1,037 events (HR, 1.09; 95% CI, 0.997–1.18; p=0.050) — a trend toward greater out
Evidence Watch Reading ToolRead This Paper Through Nine Different Lenses
The same evidence can produce very different conclusions depending on the question being asked. Explore this study through multiple physician-guided interpretive frameworks.
OVERVIEWGLP-1 RAs improved multiple health outcomes in methadone-treated OUD patients with T2D.Overview
Badge 1: ComprehensiveBadge 2: ObservationalBadge 3: High-Risk PopulationThis study explored the impact of GLP-1 receptor agonists (GLP-1 RAs) on cardiovascular, mental health, and substance use outcomes in a high-risk population of methadone-treated adults with opioid use disorder (OUD) and type 2 diabetes (T2D). The results showed significant reductions in myocardial infarctions, opioid overdoses, and suicidal ideation or attempts.
GLP-1 RAs also improved mental health outcomes by reducing major depression and anxiety disorders. Additionally, the study found that GLP-1 RA-treated patients were more likely to achieve OUD remission compared to controls.
- GLP-1 RAs reduced myocardial infarctions by 42%.
- Opioid overdose risk was cut in half with GLP-1 RA use.
- Suicidal ideation or attempts decreased by 73% among treated patients.
Key InsightGLP-1 RAs offer multifaceted benefits for methadone-treated OUD patients with T2D.Patient Takeaway
Badge 1: Patient-CentricBadge 2: Improved OutcomesBadge 3: Mental Health BenefitsFor patients on methadone who also have type 2 diabetes, GLP-1 receptor agonists (GLP-1 RAs) can significantly improve your health. The study found that these medications reduce the risk of heart attacks and opioid overdoses, which are critical concerns for this high-risk group.
Additionally, GLP-1 RAs can help manage mental health issues such as depression and anxiety, reducing suicidal ideation or attempts by 73%. This dual benefit could greatly enhance your overall quality of life.
- GLP-1 RAs reduce heart attack risk by 42%.
- Opioid overdose risk is halved with GLP-1 RA use.
- Suicidal thoughts or attempts decrease by 73%.
Patient BenefitGLP-1 RAs improve both physical and mental health in methadone-treated OUD patients with T2D.Clinician’s POV
Badge 1: Evidence-BasedBadge 2: Multimodal BenefitsBadge 3: Observational DataClinicians treating methadone-dependent patients with type 2 diabetes can consider GLP-1 receptor agonists (GLP-1 RAs) based on this study. The data show that these medications reduce the risk of myocardial infarctions and opioid overdoses, which are significant concerns in this population.
Moreover, GLP-1 RAs improve mental health outcomes by reducing major depression and anxiety disorders, and they increase the likelihood of achieving OUD remission. These findings suggest a potential role for GLP-1 RAs in comprehensive patient care.
- GLP-1 RAs reduce myocardial infarctions by 42%.
- Opioid overdose risk is reduced by 45% with GLP-1 RA use.
- Mental health benefits include reduced depression and anxiety.
Clinical ImplicationGLP-1 RAs offer multifaceted benefits for methadone-treated OUD patients with T2D, including cardiovascular, mental health, and substance use improvements.A Skeptical Read
Badge 1: Observational StudyBadge 2: Cautious OptimismBadge 3: Need for RCTsWhile the study suggests that GLP-1 receptor agonists (GLP-1 RAs) have significant benefits in methadone-treated patients with opioid use disorder and type 2 diabetes, it is important to note that this is an observational study. The findings indicate associations rather than causation.
Cautious optimism is warranted, but further randomized controlled trials are necessary to establish causality and clinical efficacy. These studies will provide more robust evidence for the role of GLP-1 RAs in this high-risk population.
- Study shows associations, not causation.
- Further RCTs needed to confirm findings.
- Benefits include reduced myocardial infarctions and opioid overdoses.
Skeptical ViewGLP-1 RA benefits are promising but require further randomized controlled trials for definitive proof.Study Critic
Badge 1: Observational LimitationsBadge 2: Potential ConfoundersBadge 3: Generalizability ConcernsCritics of the study point to its observational nature, which limits the ability to establish causality. The use of propensity score matching helps mitigate confounding factors but does not eliminate them entirely.
Additionally, the study’s findings may not generalize to all populations due to specific inclusion criteria. Further research is needed to assess the broader applicability of these results.
- Observational design limits causal inference.
- Propensity score matching reduces but does not eliminate confounding.
- Generalizability to other populations is uncertain.
Critical PerspectiveGLP-1 RA benefits are promising but observational limitations and generalizability concerns require further investigation.Compared to Past Research
Badge 1: Historical ContextBadge 2: Previous ResearchBadge 3: Evolving UnderstandingThis study builds on previous research that has explored the potential benefits of GLP-1 receptor agonists (GLP-1 RAs) in various patient populations. Earlier studies have highlighted their cardiometabolic benefits, but this is one of the first to examine their impact specifically in methadone-treated patients with opioid use disorder and type 2 diabetes.
The evolving understanding of GLP-1 RAs’ multifaceted effects continues to expand their potential applications in healthcare.
- Previous research focused on cardiometabolic benefits.
- This study extends findings to OUD and T2D populations.
- GLP-1 RA benefits are increasingly recognized across different conditions.
Historical ContextGLP-1 RA benefits in methadone-treated OUD patients with T2D build on evolving research trends.Practical Considerations
Badge 1: Practical ImplicationsBadge 2: Clinical IntegrationBadge 3: Patient CarePractically, the findings suggest that GLP-1 receptor agonists (GLP-1 RAs) could be considered as part of a comprehensive treatment plan for methadone-treated patients with opioid use disorder and type 2 diabetes. These medications offer potential benefits in reducing cardiovascular risks and improving mental health outcomes.
However, clinicians should consider individual patient factors and consult guidelines when integrating GLP-1 RAs into their care plans.
- GLP-1 RAs reduce myocardial infarctions by 42%.
- Mental health benefits include reduced depression and anxiety.
- Consideration of individual patient factors is crucial.
Practical AdviceGLP-1 RAs can be considered for methadone-treated OUD patients with T2D, but individual patient factors should guide clinical decisions.Future Directions
Badge 1: Future DirectionsBadge 2: Need for RCTsBadge 3: Broader ResearchThe future of research in this area includes conducting randomized controlled trials (RCTs) to establish causality and clinical efficacy of GLP-1 receptor agonists (GLP-1 RAs) in methadone-treated patients with opioid use disorder and type 2 diabetes. These studies will provide more robust evidence for their role in patient care.
Additionally, broader research is needed to explore the long-term effects and potential benefits of GLP-1 RAs in other high-risk populations.
- RCTs are needed to establish causality.
- Broader research on long-term effects is required.
- Future studies should explore other high-risk populations.
Future ResearchFurther RCTs and broader research are needed to fully understand the benefits of GLP-1 RAs in methadone-treated OUD patients with T2D.Misreadings & Bad-Faith Takes
Badge 1: Common MisunderstandingsBadge 2: Causal InferenceBadge 3: GeneralizabilityA common misreading of this study is that GLP-1 receptor agonists (GLP-1 RAs) definitively cause the observed health improvements. However, the study is observational and shows associations rather than causation.
Another potential misunderstanding is that these findings apply to all populations. The study’s specific inclusion criteria may limit its generalizability, so further research is needed to assess broader applicability.
- Study shows associations, not causation.
- Generalizability to other populations is uncertain.
- Misunderstandings about causal inference and generalizability are common.
Avoid MisinterpretationsAvoid misinterpreting observational findings as definitive proof of causality or assuming broad applicability without further research.Have thoughts on this? Share it:
What are GLP-1 receptor agonists?
GLP-1 receptor agonists (GLP-1 RAs) are medications that mimic the effects of glucagon-like peptide-1, a hormone that helps regulate blood sugar and has additional benefits for heart health.
How were patients selected for this study?
Patients aged 18 or older with opioid use disorder on methadone and type 2 diabetes (HbA1c ≥6.5%) were identified from the TriNetX database.
What was the study design?
This was a retrospective propensity score-matched cohort study using electronic health records to compare outcomes between GLP-1 RA users and non-users.
What were the key findings regarding cardiovascular health?
GLP-1 RA use was associated with a 42% lower risk of myocardial infarction compared to controls.
How did GLP-1 RAs affect mental health outcomes?
The study found a 73% reduction in suicidal ideation or attempts and significant reductions in major depression and anxiety disorders.
Was there an impact on opioid use disorder remission?
Yes, GLP-1 RA-treated patients were 75% more likely to achieve documented OUD remission compared to controls.
What about other substance use disorders?
The study showed a trend toward reduced alcohol use disorder and significant reductions in tobacco use disorder among GLP-1 RA users.
How did the study address potential biases?
Propensity score matching was used to balance baseline characteristics, and falsification endpoint analysis was performed to probe for residual bias.
What are the implications of these findings?
The results suggest that GLP-1 RAs may have broad benefits in methadone-treated patients with OUD and T2D, warranting further randomized controlled trials.
What are the limitations of this study?
The study is observational, so causality cannot be definitively established. Additionally, it may not generalize to all populations due to its specific inclusion criteria.
